Heart Failure Reviews最新文献

Device-based therapies for heart failure with preserved ejection fraction. 基于设备的射血分数保留型心力衰竭疗法。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-04-04 DOI: 10.1007/s10741-025-10510-5

Ryan Kim, Veraprapas Kittipibul, Sapna Bhatt, Marat Fudim

引用次数: 0

Emerging use of pulmonary artery and cardiac pressure sensing technology in the management of worsening heart failure events. 肺动脉和心脏压力传感技术在恶化心力衰竭事件管理中的新应用。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-05-09 DOI: 10.1007/s10741-025-10513-2

Matthew I Mace, Anuradha Lala, Timothy J Fendler, Andrew J Sauer

{"title":"Emerging use of pulmonary artery and cardiac pressure sensing technology in the management of worsening heart failure events.","authors":"Matthew I Mace, Anuradha Lala, Timothy J Fendler, Andrew J Sauer","doi":"10.1007/s10741-025-10513-2","DOIUrl":"10.1007/s10741-025-10513-2","url":null,"abstract":"Unplanned admissions for worsening heart failure (WHF) are the largest resource cost in heart failure (HF) management. Despite advances in pharmacological agents and interventional therapy, HF remains a global epidemic. One crucial-and costly-gap in HF management is the inability to obtain objective information to identify and quantify congestion and personalize treatment plans to effectively manage WHF events without resorting to expensive, invasive methods. Although the causes of WHF are varied and complex, the universal effect of HF decompensation is the significant decline in quality of life due to symptoms of hypervolemic congestion and the resultant reduction in cardiac output, which can be quantified via increased pulmonary venous congestion due to high intracardiac filling pressures. Accessible and reliable markers of congestion could more precisely quantify the severity of WHF events and stabilize patients earlier by interrupting and reversing this process with timely introduction or modification of evidence-based treatments. Pulmonary artery and cardiac pressure sensing tools have gained evidential credence and increased clinical uptake in recent years for the prevention and treatment of WHF, as studies of implantable hemodynamic devices have iteratively and reliably demonstrated substantial reductions in WHF events. Recent advances in sensing technologies have ranged from single-parameter invasive pulmonary artery monitors to completely non-invasive multi-parameter devices incorporating multi-sensor concept technologies aided by machine learning or artificial intelligence, although many remain investigational. This review aims to evaluate the potential for novel pulmonary artery and cardiac pressure sensing technology to reshape the management of WHF from within the hospitalized and ambulatory care environments.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"869-881"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Comprehensive Review: Unraveling the Role of Inflammation in the Etiology of Heart Failure. 综述：揭示炎症在心力衰竭病因学中的作用。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-05-14 DOI: 10.1007/s10741-025-10519-w

Diana Roman-Pepine, Adela Mihaela Serban, Roxana-Denisa Capras, Cristina Mihaela Cismaru, Adriana Gabriela Filip

{"title":"A Comprehensive Review: Unraveling the Role of Inflammation in the Etiology of Heart Failure.","authors":"Diana Roman-Pepine, Adela Mihaela Serban, Roxana-Denisa Capras, Cristina Mihaela Cismaru, Adriana Gabriela Filip","doi":"10.1007/s10741-025-10519-w","DOIUrl":"10.1007/s10741-025-10519-w","url":null,"abstract":"Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, with inflammation playing a pivotal role in its pathogenesis. This comprehensive review aims to elucidate the intricate mechanisms by which inflammation contributes to the development and progression of HF. The review synthesizes current research on the involvement of both innate and adaptive immune responses in HF, highlighting the roles of cytokines, chemokines, and other inflammatory mediators. Recent studies have demonstrated that chronic inflammation, driven by factors such as oxidative stress, neurohormonal activation, and metabolic disturbances, leads to adverse cardiac remodeling and impaired myocardial function. The review explores how systemic inflammation, characterized by elevated levels of inflammatory biomarkers like C-reactive protein (CRP) and interleukin-6 (IL-6), correlates with HF severity and outcomes. Additionally, it discusses the impact of comorbid conditions such as diabetes, obesity, and hypertension on inflammatory pathways and HF risk. The review also delves into the therapeutic implications of targeting inflammation in HF. Despite mixed results from early clinical trials, emerging evidence suggests that anti-inflammatory therapies offer benefits in specific HF phenotypes. The potential of novel therapeutic strategies, including the use of biologics and small molecule inhibitors, is examined in the context of their ability to modulate inflammatory responses and improve clinical outcomes.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"931-954"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiofrequency-based wearable sensor patch in heart failure management: a focused review. 基于射频的可穿戴传感器贴片在心力衰竭管理中的应用综述。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-04-09 DOI: 10.1007/s10741-025-10511-4

Phuuwadith Wattanachayakul, Veraprapas Kittipibul, Marat Fudim

{"title":"Radiofrequency-based wearable sensor patch in heart failure management: a focused review.","authors":"Phuuwadith Wattanachayakul, Veraprapas Kittipibul, Marat Fudim","doi":"10.1007/s10741-025-10511-4","DOIUrl":"10.1007/s10741-025-10511-4","url":null,"abstract":"ZOLL Heart Failure Management System (ZOLL HFMS) is a non-invasive, remote monitoring device that employs radiofrequency signals transmitted through an adhesive patch embedded with integrated sensors to evaluate lung fluid levels. By analyzing trends in lung fluid status and related parameters, ZOLL HFMS may facilitate the early detection of heart failure (HF) decompensation and enable timely interventions. Insights from the recent BMAD trial (Impact of heart failure management using thoracic fluid monitoring from a novel wearable sensor: Results of the Benefits of Microcor [µCor™] in Ambulatory Heart Failure) highlight its promise in those with recent HF hospitalization, demonstrating a reduction in time to first HF readmission and improvement in quality of life. In this review, we summarize data on the ZOLL HFMS, with a focus on its lung fluid analysis mechanism for early HF decompensation detection and the accuracy of its measurements compared to other modalities. Then, we examine key outcomes from the recent BMAD trial, highlighting their clinical relevance and identifying gaps that warrant further investigation in future clinical trials. Lastly, we outline potential directions for integrating this technology into routine HF management.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1093-1097"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular inhalation for targeted drug delivery in cardiac disease. 心血管吸入用于心脏疾病的靶向药物递送。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-05-23 DOI: 10.1007/s10741-025-10527-w

Alessio Alogna, Francesco Paolo Lo Muzio, Daniele Catalucci

{"title":"Cardiovascular inhalation for targeted drug delivery in cardiac disease.","authors":"Alessio Alogna, Francesco Paolo Lo Muzio, Daniele Catalucci","doi":"10.1007/s10741-025-10527-w","DOIUrl":"10.1007/s10741-025-10527-w","url":null,"abstract":"Recombinant proteins, cell, and gene therapies are collectively defined as biological drugs or biologics. These therapies have transformed the lives of millions of patients over the past decades, with the number of FDA-approved biologics increasing exponentially in recent years. However, out of approximately 700 biological therapies approved by the FDA in the last 20 years, less than 1% are indicated for cardiac pathologies. The application of biologics in cardiovascular disease has faced significant challenges, including short plasma half-life, the multifactorial complexity of cardiac disease, and the lack of efficient, non-invasive, and patient-friendly drug-delivery routes. This translational gap is particularly pressing given the immense socioeconomic burden of cardiovascular disease, which remains the leading cause of death globally and accounts for billions in annual healthcare costs and lost productivity. Inhalation-based drug delivery has recently emerged as a promising strategy for treating cardiovascular disease, with several proof-of-concept studies demonstrating its potential in heart failure, the most prevalent cardiac condition. This narrative review summarizes the latest experimental evidence in the novel field of Cardiovascular Inhalation, i.e., the lung-to-heart route for biologics. We discuss translational challenges, preclinical evidence, and future perspectives for bringing this innovative approach to clinical practice.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1103-1111"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic venous insufficiency in heart failure: exploring a reciprocal influence on cardiovascular health. 心力衰竭的慢性静脉功能不全：探索对心血管健康的相互影响。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-03-29 DOI: 10.1007/s10741-025-10508-z

Vito A Damay, Ignatius Ivan, Victor Manuel Canata Benitez

{"title":"Chronic venous insufficiency in heart failure: exploring a reciprocal influence on cardiovascular health.","authors":"Vito A Damay, Ignatius Ivan, Victor Manuel Canata Benitez","doi":"10.1007/s10741-025-10508-z","DOIUrl":"10.1007/s10741-025-10508-z","url":null,"abstract":"Chronic venous insufficiency (CVI) is a prevalent disorder, arising from venous valve incompetence and vein wall weakness, which impairs blood return and leads to venous stasis and hypertension in the lower extremities. This condition, affecting up to 40% of older adults, has been primarily considered a peripheral issue. However, growing evidence indicates its systemic impacts, notably its contribution to cardiovascular dysfunction and heart failure (HF). CVI exacerbates central venous pressure and cardiac preload, placing strain on the right heart and predisposing at-risk patients to HF. Moreover, a feedback loop exists where HF worsens CVI through increased venous stasis and fluid overload, highlighting a complex bidirectional relationship. Emerging research reveals that CVI-driven inflammation and endothelial dysfunction may accelerate adverse cardiac dysfunction. This review provides a comprehensive analysis of CVI's systemic effects, emphasizing the need for integrated cardiovascular and venous management strategies to address the reciprocal influences of CVI and HF. Such an approach could reduce disease progression and enhance outcomes for affected patients.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"819-830"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exercise prescriptions for ischemic cardiomyopathy: a scoping review. 缺血性心肌病的运动处方：范围审查。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-05-07 DOI: 10.1007/s10741-025-10521-2

Lida Koskina, Nicholas H Huerta, Shiavax J Rao, Ahmad Amin

引用次数: 0

Iron repletion in heart failure: a symptomatic win, a survival miss. 铁质补充在心力衰竭中的作用：是对症的胜利，是生存的失败。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-05-31 DOI: 10.1007/s10741-025-10532-z

Luca Monzo, Baljash Cheema, Andrew P Ambrosy, Nicolas Girerd

引用次数: 0

Cancer therapy-induced cardiotoxicity: mechanisms and mitigations. 癌症治疗诱导的心脏毒性：机制和缓解。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-06-07 DOI: 10.1007/s10741-025-10531-0

Solanki Shil, Prabodh Kumar, Kamalesh Dattaram Mumbrekar

{"title":"Cancer therapy-induced cardiotoxicity: mechanisms and mitigations.","authors":"Solanki Shil, Prabodh Kumar, Kamalesh Dattaram Mumbrekar","doi":"10.1007/s10741-025-10531-0","DOIUrl":"10.1007/s10741-025-10531-0","url":null,"abstract":"Cancer treatments like chemotherapy, radiotherapy, and combined immunotherapies have significantly increased patient survival. However, these treatments are frequently linked to cardiovascular toxicity, which has a significant impact on clinical outcomes and patient well-being. Chemotherapy, targeted therapy, and radiotherapy induce significant cellular stress in cardiomyocytes and endothelial cells, causing DNA damage, activating pro-inflammatory and pro-apoptotic signalling pathways. Cumulative damage causes cardiomyocyte loss, followed by fibrosis, resulting in pathological structural and functional remodelling of the myocardium. Endothelial cell damage disrupts vascular integrity, increasing the risk of atherosclerosis, coronary artery disease, and ischaemia. Over time, these changes can lead to clinical conditions like dilated and restrictive cardiomyopathy, which are frequently accompanied by arrhythmias and can result in heart failure and sudden cardiac death. To overcome this problem, the novel field of cardio-oncology aims to provide effective cancer treatments with a multifaceted cardioprotection approach involving pharmacological, diagnostic, natural compounds, and lifestyle interventions during and after cancer therapy. In this review, we cover the important cancer therapies, and their cardiotoxic mechanisms and detail different cardioprotective strategies aimed at mitigating these adverse effects and improve patient outcomes.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1075-1092"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond GDMT: bridging the therapeutic gap in heart failure. 超越GDMT：弥合心力衰竭的治疗差距。

IF 4.2 2区医学

Heart Failure Reviews Pub Date : 2025-09-01 Epub Date: 2025-04-30 DOI: 10.1007/s10741-025-10512-3

Laurie A Letarte, Vikram Raje, Jason P Feliberti, Steve M Antoine, Amarinder S Bindra, Dmitry M Yaranov, Amin Yehya, Rachel A Garcia, Pujan Patel, Marat Fudim, Brian Howard, Vishal N Rao, Albert Hicks, Kiran Mahmood, Richa Gupta, Allman Rollins, Amit Alam, Patrick McCann, Nirav Y Raval

引用次数: 0